ABBV vs JPM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$334.53
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+45.0%).
JPM trades at a lower forward P/E
(14.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JPM |
| Current Price |
$261.07 |
$334.53 |
| Fair Value Estimate |
$264.30 |
$485.07 |
| Upside to Fair Value |
+1.2%
|
+45.0%
|
| Market Cap |
$461.3B |
$896.4B |
| Forward P/E |
128.0x
|
14.3x
|
| EV / EBITDA |
31.0x
|
12.4x
|
| Price / Sales |
7.3x
|
5.4x
|
| Price / FCF |
22.1x
|
6.4x
|
| Revenue Growth YoY |
+12.4%
|
-168.4%
|
| Gross Margin |
70.7%
|
78.6%
|
| Operating Margin |
27.6%
|
33.7%
|
| Return on Equity |
68.0%
|
17.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
15.72%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
JPMorgan Chase & Co. operates as a leading diversified bank within the financial services sector, demonstrating a high-quality business model characterized by a strong return on equity of 17.8% and robust profitability margins including a net margin of 38.9%. Despite a significant revenue decline of 168.4% year-over-year in the most recent quarter, earnings grew by 41.2%, reflecting operational e…
Accumulation Zones
| Metric |
ABBV |
JPM |
| Zone Low |
$198.23 |
$363.80 |
| Zone High |
$224.66 |
$412.31 |
| In Buy Zone? |
No
|
Yes
|